Phajo Drugom Zhigpo

Sumitomo Pharma Subsidiary Companies in the U.S., Including Sunovion, to Combine and Form Sumitomo Pharma America

Retrieved on: 
Monday, April 3, 2023
Biotechnology, Pharmaceutical, Health, Central nervous system, Sunovion, Sumitomo Pharma, Research, Phajo Drugom Zhigpo, Patient, Roivant Sciences, Therapy, Urology, Fine chemical, Pharmaceutical industry

Sunovion Pharmaceuticals Inc., an indirect, wholly owned subsidiary of Sumitomo Pharma Co. Ltd, announced today that it will combine with affiliate companies Sumitomo Pharma America Holdings, Inc., Sumitovant Biopharma Ltd., Myovant Sciences, Inc., Urovant Sciences, Inc., Enzyvant Therapeutics, Inc., and Sumitomo Pharma Oncology, Inc. to form Sumitomo Pharma America, Inc. effective July 1, 2023.

Key Points: 
  • Sunovion Pharmaceuticals Inc., an indirect, wholly owned subsidiary of Sumitomo Pharma Co. Ltd, announced today that it will combine with affiliate companies Sumitomo Pharma America Holdings, Inc., Sumitovant Biopharma Ltd., Myovant Sciences, Inc., Urovant Sciences, Inc., Enzyvant Therapeutics, Inc., and Sumitomo Pharma Oncology, Inc. to form Sumitomo Pharma America, Inc. effective July 1, 2023.
  • Spirovant Sciences, Inc., Sumitovant’s remaining wholly owned subsidiary, will operate as a standalone company under Sumitomo Pharma America.
  • Sumitovant’s current CEO Myrtle Potter will serve as President and CEO of Sumitomo Pharma America upon completion of the combination.
  • Hiroshi Nomura, President and CEO of Sumitomo Pharma, said, “We remain deeply committed to addressing pressing health challenges and believe Sumitomo Pharma America will serve as a valuable growth engine.

Sumitovant Biopharma Helps Identify More Than 80 Peptide Drug Candidates for Neochromosome's Differentiated Manufacturing Technology

Retrieved on: 
Thursday, January 19, 2023
Partnership, Therapy, Drug discovery, Intelligence, Research, NLP, Nature, Phajo Drugom Zhigpo, Library, Natural language processing, Pharmaceutical industry, Neochromosome

NEW YORK, Jan. 19, 2023 /PRNewswire/ -- Sumitovant Biopharma, Inc. ("Sumitovant"), a technology-driven biopharmaceutical company accelerating the development and commercialization of novel therapeutics, announced it has identified more than 80 peptide drug candidates for manufacturing, using the company's DrugOME™ computational platform.

Key Points: 
  • NEW YORK, Jan. 19, 2023 /PRNewswire/ -- Sumitovant Biopharma, Inc. ("Sumitovant"), a technology-driven biopharmaceutical company accelerating the development and commercialization of novel therapeutics, announced it has identified more than 80 peptide drug candidates for manufacturing, using the company's DrugOME™ computational platform.
  • The identified protein candidates enable Neochromosome to pursue actionable opportunities for its genome-scale engineering technology and its neoYeast™ protein discovery and manufacturing platform.
  • "This collaboration enabled us to identify promising peptide drug candidates for neoYeast including those that have the potential to positively impact unmet medical needs.
  • By utilizing this platform, alongside Sumitovant's technologists and team of life-sciences experts, Sumitovant has developed a novel approach to drug discovery and development – from research through commercialization.

Neochromosome and Sumitovant Biopharma Announce Successful Collaboration to Accelerate Protein Drug Discovery and Improve Manufacturing

Retrieved on: 
Thursday, January 19, 2023
Technology, Research, Genetics, Software, Biotechnology, Health, Pharmaceutical, Science, Artificial Intelligence, Entrepreneurship, Algorithm, Cytokine, Machine learning, Vaccine, Partnership, Protein, Artificial intelligence, Therapy, Drug discovery, Patient, Intelligence, Antibody, Enzyme, NLP, Nature, Peptide, Phajo Drugom Zhigpo, Library, Natural language processing, Fine chemical, Neochromosome

This collaboration combines Neochromosome’s neoYeast™ platform with Sumitovant’s DrugOME™ computational ecosystem to identify novel proteins that would benefit from non-canonical amino acid chemistries that are not found in nature.

Key Points: 
  • This collaboration combines Neochromosome’s neoYeast™ platform with Sumitovant’s DrugOME™ computational ecosystem to identify novel proteins that would benefit from non-canonical amino acid chemistries that are not found in nature.
  • As part of the collaboration, Sumitovant utilized a proprietary combination of natural language processing (NLP), machine learning, artificial intelligence, and computational algorithms to uncover opportunities for Neochromosome to improve the discovery and manufacturing of proteins limited by evolution and traditional manufacturing processes.
  • Sumitovant utilized DrugOME to systematically and comprehensively explore libraries of traditional and non-traditional data sources to recommend targeted protein development candidates for neoYeast.
  • “Sumitovant’s extensive life-sciences expertise, combined with our in-house technology platforms, provide a unique opportunity for our portfolio assets as well as external partners to accelerate the drug discovery, development, and commercialization processes.”
    The collaboration launched in 2022 as Neochromosome pursues opportunities to improve drug discovery, development, and manufacturing across multiple biologic types, including antibodies, enzymes, peptides, cytokines, and vaccines.

Secondcell Bio Publishes Biotechnology for Improved Drug Discovery Originating from The Rockefeller University

Retrieved on: 
Wednesday, September 15, 2021
Library, Rockefeller University, Garbage, United States Air Force Scientific Advisory Board, Gene, Scientist, MiR-132, NOAAS Oregon II (R 332), Nobel Prize, United Airlines Flight 232, Time, Research, Springer Nature, Biology, Plasmid, Pressure, Gene expression, GABAA, CHO, Epithelium, Kaay Raav Tumhi, CFTR, Biotechnology Letters, RNA transfection, Sickle cell disease, Chromosome, CRISPR, Investment, Cell, Biotechnology, Drug discovery, FDA, Genetic engineering, Neuron, A-DNA, G protein-coupled receptor, Subtypes of HIV, Technology, DNA, MCS, Abstract, Membrane protein, HEK, Chromolithography, RNA, Zinc finger protein 532, Goal, Method, Cell engineering, Efficiency, Phajo Drugom Zhigpo, LLC, Epistasis, GPCR, Multiple, Industry, Partnership, Disease, Flow cytometry, Scale, Forestry, Pharmaceutical industry, Vaccine, Fine chemical, Antibiotics

"Little more than a random and highly inefficient enterprise, drug discovery today is "garbage in, garbage out" enterprise.

Key Points: 
  • "Little more than a random and highly inefficient enterprise, drug discovery today is "garbage in, garbage out" enterprise.
  • Currently, the industry average failure rate for drug discovery programs in pharmaceutical companies is reported to be approximately 98%.
  • This work was performed by Chromocell Corporation, a biotechnology company spun out of The Rockefeller University based upon the technology.
  • Secondcell, Secondcell Bio, Cellbrary, Cellbraries, Chromo-Plasmid, pChromo-Plasmid, Chromo-Tag, Drugomics, Drug Discovery at Scale, and the Secondcell Bio logo are trademarks of Secondcell Bio, LLC.